Follow BioVie to never miss an important update.
BioVie is scheduled to report its quarterly results on Monday, November 9. As a clinical-stage biotech, the company does not yet have sales, so the focus will be on its cash levels and any updates on the timeline for its Parkinson's and Alzheimer's drug trials.
BioVie has been invited to present data on its lead drug candidate, bezisterim, at a workshop hosted by the National Institutes of Health. The presentation will focus on how the drug might help patients with Long COVID. While the company's primary focus is on Parkinson's and Alzheimer's, this invitation suggests that federal health researchers are taking an interest in the drug's ability to reduce inflammation. This could eventually open up a second path for the drug if it succeeds in clinical trials.
Source: GlobeNewsWire
BioVie presented data from a small Phase 2 study showing that its drug, bezisterim, helped Parkinson's patients who have high levels of inflammation. These patients saw statistically significant improvements in both their physical movements and non-motor symptoms over 12 weeks.
This is a key win for the company's theory that targeting brain inflammation can treat the underlying disease rather than just the symptoms. The next step is to see if these results hold up in a much larger Phase 3 trial, which is the final stage of testing required for FDA approval.
Source: Proactive Investors
Results from a Phase 2 trial showed that BioVie's drug significantly improved fatigue and cognitive impairment, often called brain fog, in patients with severe Long COVID. The benefits were most visible in patients who started the trial with the most severe symptoms.
These results provide more evidence that the drug is successfully targeting inflammation in the body. While Parkinson's remains the main value driver for the stock, proving the drug works in other inflammatory conditions reduces the risk that the entire company depends on a single trial outcome.
Source: Proactive Investors
Management has a history of beating their own targets, though recent misses suggest they are struggling to predict the costs of running multiple clinical trials at once.